| Ana Maria Ramirez Berlioz, MD | |
|
4722 Eagleridge Cir, Pueblo, CO 81008-2344 | |
| (719) 595-7563 | |
| (719) 595-7907 |
| Full Name | Ana Maria Ramirez Berlioz |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 11 Years |
| Location | 4722 Eagleridge Cir, Pueblo, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386025229 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | DR.0063733 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Parkview Medical Center, Inc | Pueblo, CO | Hospital |
| St Mary Corwin Med Ctr, Centura Health | Pueblo, CO | Hospital |
| San Luis Valley Health | Alamosa, CO | Hospital |
| Rio Grande Hospital | Del norte, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Parkview Ancillary Services Corporation | 4385722511 | 267 |
News Archive
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) today announced results for the three and six months ended June 30, 2009.
Epigem, a high-tech British micro-engineering company, has challenged 15 students from the Durham University-led SOFI CDT (Centre for Doctoral Training in Soft Matter and Functional Interfaces), to come up with solutions to prevent a dangerous carcinogen from contaminating milk.
A new study suggests that blocking an enzyme called PRMT5 in tumor cells could be a promising new strategy for the treatment of glioblastoma (GB), the most aggressive and lethal form of brain cancer.
The drug vismodegib (trade name: Erivedge) is approved for the treatment of patients with two forms of basal cell carcinoma: symptomatic metastatic BCC and locally advanced BCC inappropriate for surgery or radiotherapy.
› Verified 1 days ago
| Entity Name | Parkview Ancillary Services Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982878765 PECOS PAC ID: 4385722511 Enrollment ID: O20080429000248 |
News Archive
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) today announced results for the three and six months ended June 30, 2009.
Epigem, a high-tech British micro-engineering company, has challenged 15 students from the Durham University-led SOFI CDT (Centre for Doctoral Training in Soft Matter and Functional Interfaces), to come up with solutions to prevent a dangerous carcinogen from contaminating milk.
A new study suggests that blocking an enzyme called PRMT5 in tumor cells could be a promising new strategy for the treatment of glioblastoma (GB), the most aggressive and lethal form of brain cancer.
The drug vismodegib (trade name: Erivedge) is approved for the treatment of patients with two forms of basal cell carcinoma: symptomatic metastatic BCC and locally advanced BCC inappropriate for surgery or radiotherapy.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ana Maria Ramirez Berlioz, MD Po Box 560825, Denver, CO 80256-0825 Ph: (719) 595-7580 | Ana Maria Ramirez Berlioz, MD 4722 Eagleridge Cir, Pueblo, CO 81008-2344 Ph: (719) 595-7563 |
News Archive
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) today announced results for the three and six months ended June 30, 2009.
Epigem, a high-tech British micro-engineering company, has challenged 15 students from the Durham University-led SOFI CDT (Centre for Doctoral Training in Soft Matter and Functional Interfaces), to come up with solutions to prevent a dangerous carcinogen from contaminating milk.
A new study suggests that blocking an enzyme called PRMT5 in tumor cells could be a promising new strategy for the treatment of glioblastoma (GB), the most aggressive and lethal form of brain cancer.
The drug vismodegib (trade name: Erivedge) is approved for the treatment of patients with two forms of basal cell carcinoma: symptomatic metastatic BCC and locally advanced BCC inappropriate for surgery or radiotherapy.
› Verified 1 days ago
Dr. Christopher John Calcagno, D.O. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1600 N. Grand Ave., Ste. 300, Pueblo, CO 81003 Phone: 719-562-2001 Fax: 719-562-2742 | |
Christopher Jon Stark, Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 400 W 16th St, Pueblo, CO 81003 Phone: 719-595-2218 Fax: 719-595-7994 | |
Greg Alan Bowman, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1600 N Grand Ave, Suite 500, Pueblo, CO 81003 Phone: 719-545-0663 Fax: 719-595-7903 | |
Lauren E. Sullenberger, DO Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 902 Lakeview Ave, Pueblo, CO 81004 Phone: 719-557-5855 Fax: 719-557-5097 | |
Peter Lochow, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3670 Parker Blvd Ste 101, Pueblo, CO 81008 Phone: 719-564-1544 Fax: 719-924-1593 | |
Dr. Raj Vashistha, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3670 Parker Blvd., Ste 101, Pueblo, CO 81008 Phone: 719-564-1544 Fax: 719-924-1592 | |
Dr. Rebecca Elizabeth Holder, D.O. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1207 Pueblo Boulevard Way, Pueblo, CO 81005 Phone: 719-542-0032 Fax: 719-553-1904 |